Signals Blog

Yesterday, for the first time in seven years, the House of Commons Standing Committee on Health heard testimony on the current status of stem cell research in Canada. Although the topics covered by MPs during the Committee hearings did not seem to reflect any immediate legislative priorities, nevertheless it was a welcome opportunity for the stem cell community to provide input to Parliament. Three members of the Stem Cell Network gave testimony during the proceedings:

Dr. Michael Rudnicki, Scientific Director of the Stem Cell Network, talked to the recent advances in science, noting in particular the profound impact of the discovery of iPS cells, the increasing use of stem cells to screen for new or safer drugs, and the clinical trials anticipated over the next five years. A full copy of his remarks can be downloaded in both French and English.

Drew Lyall, Executive Director of the Stem Cell Network, and Board Chair of the Canadian Stem Cell Foundation, spoke next about the opportunity stem cell research represents for Canada to improve patient lives, reduce the economic burden of health care, and create new jobs. However, he also warned that Canada risks losing its leadership in this field without further substantial investment from the federal government. A full copy of his remarks are available in French and English.

Finally Dr. Janet Rossant, Chief of Research at SickKids Hospital in Toronto, and Deputy Director of the Stem Cell Network spoke about some of the regulatory challenges to the research environment, in particular the overlapping mandates of the Assisted Human Reproduction Agency of Canada, CIHR’s Stem Cell Oversight Committee, and the Tri-Council Policy Statement on research ethics. Dr. Rossant also spoke to the ongoing uncertainty caused by the absence of a decision from the Supreme Court of Canada on the constitutionality of the Act with respect to assisted human reproduction. A full copy of her remarks can be found here.

Testimony was also given by Cancer Care Manitoba, in particular by Dr. Dhali Dhaliwal, President & CEO, and Dr. Donna Wall, a physician in pediatric hematology/oncology.

Beyond issues relating to research advances, the funding environment, and regulation, a number of other topics were touched upon in some depth:

  • Potential opportunities to increase participation, particularly amongst minority groups, in OneMatch the Canadian bone marrow transplant donor registry managed by Canadian Blood Services. It is an area in which Joy Smith, Chair of the Committee has taken a particular interest.
  • The need to establish a Canadian public cord blood bank, and the challenges in securing funding from the Provinces and Territories to do so, despite unanimity amongst them that it needs to be done.
  • The risks face by Canadian patients seeking therapies from clinics outside of the country, offering therapies for which there is little scientific evidence. This issue of “stem cell tourism” is one we have discussed before.
  • Members also enquired about the Stem Cell Charter, a call to action for scientists patients and the public prepared by the Canadian Stem Cell Foundation, asking signatories to voice their support for stem cell research. To date over 4,000 people have signed the Charter.

While everyone recognizes the ongoing constraints imposed by the current fiscal environment, more can still be done to support stem cell research, and to advance therapies to the clinic more rapidly. Stem cells are back on Parliament’s agenda, so if you feel strongly write to your MP, or directly to one of the Members of the Standing Committee.


The following two tabs change content below.

Stem Cell Network